160 related articles for article (PubMed ID: 35480282)
1. Synthesis and biological evaluation of PET tracers designed for imaging of calcium activated potassium channel 3.1 (K
Brömmel K; Konken CP; Börgel F; Obeng-Darko H; Schelhaas S; Bulk E; Budde T; Schwab A; Schäfers M; Wünsch B
RSC Adv; 2021 Sep; 11(48):30295-30304. PubMed ID: 35480282
[TBL] [Abstract][Full Text] [Related]
2. Imaging of the calcium activated potassium channel 3.1 (K
Konken CP; Heßling K; Thale I; Schelhaas S; Dabel J; Maskri S; Bulk E; Budde T; Koch O; Schwab A; Schäfers M; Wünsch B
Arch Pharm (Weinheim); 2022 Dec; 355(12):e2200388. PubMed ID: 36161669
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of KCa3.1 by depolarisation and 2-aminoethoxydiphenyl borate (2-APB) during Ca²⁺ release activated Ca²⁺ (CRAC) entry in human erythroleukemia (HEL) cells: Implications for the interpretation of 2-APB inhibition of CRAC entry.
Littlechild R; Zaidman N; Khodaverdi D; Mason MJ
Cell Calcium; 2015 Feb; 57(2):76-88. PubMed ID: 25601026
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the potassium channel K
Staal RGW; Khayrullina T; Zhang H; Davis S; Fallon SM; Cajina M; Nattini ME; Hu A; Zhou H; Poda SB; Zorn S; Chandrasena G; Dale E; Cambpell B; Biilmann Rønn LC; Munro G; Mӧller T
Eur J Pharmacol; 2017 Jan; 795():1-7. PubMed ID: 27876619
[TBL] [Abstract][Full Text] [Related]
5. Targeting K
Todesca LM; Maskri S; Brömmel K; Thale I; Wünsch B; Koch O; Schwab A
Cell Physiol Biochem; 2021 May; 55(S3):131-144. PubMed ID: 34043300
[TBL] [Abstract][Full Text] [Related]
6. Repurposing the KCa3.1 inhibitor senicapoc for Alzheimer's disease.
Jin LW; Lucente JD; Nguyen HM; Singh V; Singh L; Chavez M; Bushong T; Wulff H; Maezawa I
Ann Clin Transl Neurol; 2019 Apr; 6(4):723-738. PubMed ID: 31019997
[TBL] [Abstract][Full Text] [Related]
7. Imaging of K
Thale I; Maskri S; Grey L; Todesca LM; Budde T; Maisuls I; Strassert CA; Koch O; Schwab A; Wünsch B
ChemMedChem; 2023 Jan; 18(2):e202200551. PubMed ID: 36315933
[TBL] [Abstract][Full Text] [Related]
8. K
Glaser F; Hundehege P; Bulk E; Todesca LM; Schimmelpfennig S; Nass E; Budde T; Meuth SG; Schwab A
Sci Rep; 2021 Sep; 11(1):18330. PubMed ID: 34526525
[TBL] [Abstract][Full Text] [Related]
9. Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease.
Paka L; Smith DE; Jung D; McCormack S; Zhou P; Duan B; Li JS; Shi J; Hao YJ; Jiang K; Yamin M; Goldberg ID; Narayan P
World J Gastroenterol; 2017 Jun; 23(23):4181-4190. PubMed ID: 28694658
[TBL] [Abstract][Full Text] [Related]
10. The Ca(2+)-activated K(+) channel KCa3.1 compartmentalizes in the immunological synapse of human T lymphocytes.
Nicolaou SA; Neumeier L; Peng Y; Devor DC; Conforti L
Am J Physiol Cell Physiol; 2007 Apr; 292(4):C1431-9. PubMed ID: 17151145
[TBL] [Abstract][Full Text] [Related]
11. Novel phenolic inhibitors of small/intermediate-conductance Ca²⁺-activated K⁺ channels, KCa3.1 and KCa2.3.
Oliván-Viguera A; Valero MS; Murillo MD; Wulff H; García-Otín AL; Arbonés-Mainar JM; Köhler R
PLoS One; 2013; 8(3):e58614. PubMed ID: 23516517
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Intermediate-Conductance Calcium-Activated K Channel (KCa3.1) and Fibroblast Mitogenesis by α-Linolenic Acid and Alterations of Channel Expression in the Lysosomal Storage Disorders, Fabry Disease, and Niemann Pick C.
Oliván-Viguera A; Lozano-Gerona J; López de Frutos L; Cebolla JJ; Irún P; Abarca-Lachen E; García-Malinis AJ; García-Otín ÁL; Gilaberte Y; Giraldo P; Köhler R
Front Physiol; 2017; 8():39. PubMed ID: 28197106
[TBL] [Abstract][Full Text] [Related]
13. Effect of the KCa3.1 blocker, senicapoc, on cerebral edema and cardiovascular function after cardiac arrest - A randomized experimental rat study.
Hansen FB; Secher N; Mattson T; Løfgren B; Simonsen U; Granfeldt A
Resusc Plus; 2021 Jun; 6():100111. PubMed ID: 34223371
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of Small-Molecule Fluorescent Probes for the In Vitro Imaging of Calcium-Activated Potassium Channel K
Brömmel K; Maskri S; Maisuls I; Konken CP; Rieke M; Pethő Z; Strassert CA; Koch O; Schwab A; Wünsch B
Angew Chem Int Ed Engl; 2020 May; 59(21):8277-8284. PubMed ID: 32097518
[TBL] [Abstract][Full Text] [Related]
15. TRPM2 Oxidation Activates Two Distinct Potassium Channels in Melanoma Cells through Intracellular Calcium Increase.
Ferrera L; Barbieri R; Picco C; Zuccolini P; Remigante A; Bertelli S; Fumagalli MR; Zifarelli G; La Porta CAM; Gavazzo P; Pusch M
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445066
[TBL] [Abstract][Full Text] [Related]
16. Repurposing the K
Lee RD; Chen YJ; Nguyen HM; Singh L; Dietrich CJ; Pyles BR; Cui Y; Weinstein JR; Wulff H
Transl Stroke Res; 2024 Jun; 15(3):518-532. PubMed ID: 37088858
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic ion channel interactions in red cells of patients with Gárdos channelopathy.
Jansen J; Qiao M; Hertz L; Wang X; Fermo E; Zaninoni A; Colombatti R; Bernhardt I; Bianchi P; Kaestner L
Blood Adv; 2021 Sep; 5(17):3303-3308. PubMed ID: 34468723
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the K
Organ L; Bacci B; Koumoundouros E; Kimpton WG; Samuel CS; Nowell CJ; Bradding P; Roach KM; Westall G; Jaffar J; Snibson KJ
Am J Respir Cell Mol Biol; 2017 Apr; 56(4):539-550. PubMed ID: 28060543
[TBL] [Abstract][Full Text] [Related]
19. Calcium-dependent potassium channels control proliferation of cardiac progenitor cells and bone marrow-derived mesenchymal stem cells.
Vigneault P; Naud P; Qi X; Xiao J; Villeneuve L; Davis DR; Nattel S
J Physiol; 2018 Jun; 596(12):2359-2379. PubMed ID: 29574723
[TBL] [Abstract][Full Text] [Related]
20. Radiosynthesis, in vitro and preliminary in vivo evaluation of the novel glutamine derived PET tracers [
Baguet T; Verhoeven J; Pauwelyn G; Hu J; Lambe P; De Lombaerde S; Piron S; Donche S; Descamps B; Goethals I; Vanhove C; De Vos F; Beyzavi MH
Nucl Med Biol; 2020; 86-87():20-29. PubMed ID: 32447069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]